title: [Pharmacological properties of rilpivirine (Edurant Tablet), a new drug for the treatment of HIV, and results of its clinical studies].
authors.affiliation: mmuramat@its.jnj.com
authors.forename: Michiko
authors.initials: M
authors.lastname: Iwata
authors.forename: Koji
authors.initials: K
authors.lastname: Shikinami
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagino
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Harada
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D009570:Nitriles / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000068696:Rilpivirine
chemical_list: D019380:Anti-HIV Agents; D009570:Nitriles; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D000068696:Rilpivirine